HomeAll New Products Listed Chronologically

All New Products Listed Chronologically

Catalog No. Product Name Information Isotype
A2457 Xentuzumab (Anti-IGF-1) Xentuzumab (Anti-IGF-1) is a recombinant a humanized monoclonal antibody that targets IGF ligands IGF-1 and IGF-2. Xentuzumab inhibits both of IGF-1 and IGF-2 growth-promoting signalling and suppresses AKT activation. MW: 145.5 KD. Aug 10 2023
A2460 Anifrolumab (Anti-IFNAR1) Anifrolumab (Anti-IFNAR1) is a human monoclonal antibody. It is a type I interferon (IFN) receptor antagonist, that blocks the activity of type I interferon. Anifrolumab can be used in research of systemic lupus erythematosus (SLE). MW: 145.5 KD. Aug 10 2023
A2461 Sifalimumab (Anti-IFNa1) Sifalimumab (Anti-IFNa1) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. MW: 145.5 KD. Aug 10 2023
A2462 Feladilimab (Anti-ICOS / CD278) Feladilimab (Anti-ICOS/CD278) is humanized IgG4 anti-ICOS agonist monoclonal antibody. Feladilimab binds to ICOS-expressing T cells. Feladilimab has potential for its use in cancer research. MW: 145.5 KD. Aug 10 2023
A2463 Vopratelimab (Anti-ICOS / CD278) Vopratelimab (Anti-ICOS / CD278) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that binds specifically to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab exhibits antitumor immune response. MW: 145.5 KD. Aug 10 2023
A2464 Bersanlimab (Anti-ICAM1 / CD54) Bersanlimab (Anti-ICAM1 / CD54) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anticancer effects. MW: 145.5 KD. Aug 10 2023
A2465 Anti-HLA-DR Anti-HLA-DR (IMMU-114) is a humanized anti-human leukocyte antigen-DR (HLA-DR) moAb, that depletes APCs and reduces alloreactive T cells. MW: 145.5 KD. Aug 10 2023
A2466 Derlotuximab (Anti-Histone H1) Derlotuximab is a recombinant human monoclonal antibody that targets DNA/histone (H1) complex. It is potentially used in the treatment of Glioblastoma multiforme (GBM), Cancers, brain, malignant glioma, Solid tumors. It is also used in certain immunoassay techniques. MW: 145.5 KD. Aug 10 2023
A2467 Telisotuzumab (Anti-HGFR / c-Met) Telisotuzumab (Anti-HGFR / c-Met) is a monoclonal antibody that targets c-Met. MW: 145.64 KD. Aug 10 2023
A2468 Onartuzumab (Anti-HGFR / c-Met) Onartuzumab (Anti-HGFR / c-Met) is a unique, humanized and affinity-matured monovalent (one-armed) monoclonal antibody against the MET receptor. Onartuzumab potently inhibits HGF binding and receptor phosphorylation and signaling. Onartuzumab has antibody-like pharmacokinetics and antitumor activity. MW: 144.64 KD. Aug 10 2023
A2469 Rilotumumab (Anti-HGF / SF) Rilotumumab (Anti-HGF / SF) is a monoclonal antibody that inhibits HGF/MET-driven signaling. Rilotumumab shows anti-tumor activity, and can be used in castration-resistant prostate cancer (CRPC) and solid tumor research. MW: 145.5 KD. Aug 10 2023
A2470 Anti-Hepcidin / HAMP Anti-Hepcidin / HAMP (LY2787106) is a fully humanized monoclonal antibody againsts hepcidin. It is currently in phase I human trials for cancer-related anemia. It binds to hepcidin and prevents its binding to the iron exporting protein ferroportin and prevents hepcidin-induced internalization and degradation of ferroportin and increases ferroportin-mediated iron export. MW: 145.5 KD. Aug 10 2023
A2471 Anti-HBEGF Anti-HBEGF (U3-1565) is a humanized monoclonal antibody against human heparin-binding EGF-like growth factor (HBEGF) and exhibits potential antineoplastic activity. It binds to HBEGF and blocks the binding of HBEGF to the EGF receptors which prevents EGF receptor activation and results in subsequent induction of cell growth signaling. MW: 145.5 KD. Aug 10 2023
A2472 Indusatumab (Anti-GUCY2C) Indusatumab (Anti-GUCY2C) is an monoclonal antibody that targets GUCY2C (Guanylate cyclase 2C). MW: 145.5 KD. Aug 10 2023
A2473 Talquetamab (Anti-GPRC5D) Talquetamab (Anti-GPRC5D) is a humanized bispecific antibody that binds to GPRC5D (member of G protein-coupled receptor family C5 group D) and CD3 to induce T cell-mediated killing of GPRC5D-expressing MM cells through T cell recruitment and activation. Talquetamab exhibits antitumor activity. MW: 145.5 KD. Aug 10 2023
A2474 Petosemtamab (Anti-GPR49 / LGR5) Petosemtamab (Anti-GPR49 / LGR5) is an monoclonal antibody that targets GPR49/LGR5. It blocks the appearance of metastases and slows the growth of primary tumors in experimental cancer models. Petosemtamab can be used in the research of solid tumors, such as head and neck squamous cell carcinoma (HNSCC), metastatic colorectal cancer (CRC). MW: 145.5 KD. Aug 10 2023
A2475 Glembatumumab (Anti-GPNMB) Glembatumumab is a fully human IgG2 monoclonal antibody directed against the extracellular structural domain of GPNMB expressed in human breast cancer and melanoma. MW: 145.5 KD. Aug 10 2023
A2476 Codrituzumab (Anti-GPC3 / Glypican-3) Codrituzumab is a monoclonal antibody targeting GPC3 (glypican-3) which is an oncofetal protein expressed on the cell surface of hepatocellular carcinoma (HCC). Codrituzumab induces antibody-dependent cellular cytotoxicity (ADCC) and inhibits tumor growth. MW: 150 KD. Aug 10 2023
A2477 Anti-GPA33 Anti-GPA33 (KRN330) is a monoclonal antibody that targets GPA33, a tumor-associated antigen (TAA) which is overexpressed on the surface of certain tumor cells. It exhibits potential immunostimulatory and antineoplastic activities. MW: 145.5 KD. Aug 10 2023
A2478 Glenzocimab (Anti-GP6 / Glycoprotein-6) Glenzocimab (Anti-GP6 / Glycoprotein-6) is a Fab fragment of humanized anti-GPVI monoclonal antibody. Glenzocimab inhibits collagen-induced platelet aggregation. Glenzocimab has the potential for the research of acute ischemic stroke. MW: 145.5 KD. Aug 10 2023